|
|
|
|
Insulin study could lead to new dosage devices
Buy Maxalt Without a Prescription Buy no Prescription Strattera Order Tamiflu no Prescription Online Buy Medrol Without a Prescription Buy Naltrexone Without a Prescription Buy no Prescription Antabuse Online Buy Boniva no Prescription Buy Propecia...
|
|
|
Bone Up On This Potential Blockbuster
Investors patiently waiting for the Food and Drug Administration to approve Amgen's (Nasdaq: AMGN) bone drug Prolia may finally be seeing the light at the end of the tunnel.Yesterday Amgen released positive results from its third phase 3 trial pitting Prolia...
|
|
|
Bone Up On This Potential Blockbuster
Investors patiently waiting for the Food and Drug Administration to approve Amgen's (Nasdaq: AMGN) bone drug Prolia may finally be seeing the light at the end of the tunnel.Yesterday Amgen released positive results from its third phase 3 trial pitting Prolia...
|
|
|
The Columbus Dispatch, Ohio, Joe Blundo column: Feel blue? You must be taking Avatar [The Columbus Dispatch, O
4--I've noticed that the marketing whizzes at pharmaceutical companies favor three-syllable names (Cymbalta, Lipitor, Nasonex) and love the letter 'V' (Viagra, Prevacid, Avodart, Boniva).Maybe that's why Avatar, the blockbuster 3-D movie directed by...
|
|
|
Judge refuses to dismiss Fosamax case, sets trial
NEW YORK (Reuters) - A Manhattan federal judge refused on Friday to dismiss a lawsuit alleging that Merck & Co Inc's osteoporosis drug Fosamax caused jaw damage to an Indiana woman during the nearly eight years she took the pill.District Judge John...
|
|
|
Osteoporosis meds may cut breast cancer risk: Study
NEW YORK ' Women who took a commonly used class of osteoporosis drugs called bisphosphonates had significantly fewer invasive breast cancers than women not using the bone-strengthening pills, according to a new analysis of data from the Women's Health...
|
|
|
Sexual health products tops in DTC-driven web traffic
NuvaRing and Latisse lead the pack in DTC-driven traffic to their brand.com sites, according to Manhattan Research.The research firm's ePharma Consumer survey found that Merck Contraceptive NuvaRing jumped five spots to take the top spot for ad-driven...
|
|
|
NuvaRing Tops List of Most Visited Sites Via TV
Market-analyst firm Manhattan Research, on Tuesday, released a list of the top branded pharma Web sites based on traffic generated from consumer television ads.Topping the list was the contraceptive NuvaRing, which was all over television this past year.
|
|
|
Manhattan Research Releases New Research on DTC's Impact on Pharma Website Visitation
NuvaRing and Latisse are the top pharmaceutical brands in terms of having the highest percentage of overall product website traffic driven by their DTC television advertisements, according to pharmaceutical and healthcare market research company Manhattan...
|
|
|
Coakley Choice of Big Pharma
Democrat Martha Coakley, wealthy, establishment liberal appointed by the machine to take the Senate seat vacated by the death of Ted Kennedy, held a big fund-raiser last evening that surely re-inflated her campaign coffers and will allow a final hour blitz that...
|
|
|
Manhattan Research Releases New Research on DTCs Impact on Pharma Website Visitation
Top Pharma Product Sites Among the Topics of an eMarketing Webinar - January 21 NEW YORK, January 12, 2010 NuvaRing and Latisse are the top pharmaceutical brands in terms of having the highest percentage of overall product website traffic driven by their DTC...
|
|
|
Glaxo Exercises Drug Option
Recently, GlaxoSmithKline (GSK) exercised its option to obtain exclusive license regarding further development and commercialization of ChemoCentryx's Traficet-EN, a specific CCR9 antagonist.The drug candidate is meant for the treatment of inflammatory bowel...
|
|
|
Glaxo Exercises Drug Option
Recently, GlaxoSmithKline (GSK) exercised its option to obtain exclusive license regarding further development and commercialization of ChemoCentryx's Traficet-EN, a specific CCR9 antagonist.The drug candidate is meant for the treatment of inflammatory bowel...
|
|
|
Glaxo Exercises Drug Option - Zibb.com
Companies: Bristol-Myers Squibb Co.(BMY), GlaxoSmithKline plc (GSK), Merck & Co., Inc. (MRK) Recently, GlaxoSmithKline (GSK) exercised its option to obtain exclusive license regarding further development and commercialization of ChemoCentryx's Traficet...
|
|
|
Manhattan Research Releases New Research on DTCs Impact on Pharma Website Visitation
Top Pharma Product Sites Among the Topics of an eMarketing Webinar - January 21 (PRWEB) January 12, 2010 -- NuvaRing and Latisse are the top pharmaceutical brands in terms of having the highest percentage of overall product website traffic driven by their DTC...
|
|
|
Strengthening Bones without Upsetting Stomach
If you have more to say, post a comment below!I am 62 years old and just had my second bone density test. I was told I have osteopenia and should take Boniva. I have been lactose intolerant for many years. Consuming milk gives me smelly gas,...
|
|
|
Osteoporosis meds may cut breast cancer risk: study
-0400 (Reuters Health) By Bill Berkrot NEW YORK (Reuters) - Women who took a commonly used class of osteoporosis drugs called bisphosphonates had significantly fewer invasive breast cancers than women not using the bone-strengthening pills, according to a new...
|
|
|
Studies: Bone drugs may help prevent breast cancer
New results from a landmark womens health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer.Women who already were using these medicines when the study began were about one-third less...
|
|
|
Bone-building drugs may help prevent breast cancer: study
Increases the bookmark twitter facebook digg Google Windowslive Delicious buzz friendfeed Linkedin diigo reddit stumbleupon Bone-building drugs such as Fosamax and Actonel might help prevent breast cancer, according to two new studies presented Thursday at a...
|
|
|
Osteoporosis meds may cut breast cancer risk
NEW YORK (Reuters) - Women who took a commonly used class of osteoporosis drugs called bisphosphonates had significantly fewer invasive breast cancers than women not using the bone-strengthening pills, according to a new analysis of data from the Women's Health...
|
|
|
U.S. lawsuit over Merck bone drug Fosamax dismissed
-0400 (Reuters Health) * Plaintiff failed to show Fosamax caused injury * Ruling follows mistrial in earlier case * Merck shares close 4 cents lower By Jonathan Stempel NEW YORK (Reuters) - A Manhattan federal judge has dismissed a lawsuit alleging that Merck ...
|
